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after RT, is probably due to the smaller sample size. No 
significant differences according to type and duration of HT 
were observed. Newer strategies to reduce the negative 
impact on QoL of HT and further analysis based on PC-
specific assessment tools appear to be justified. 
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Purpose/Objective: To report 5-year clinical outcomes and 
late toxicity in prostate cancer patients (pts) treated with 
Image Guided Radiotherapy (IGRT) Moderate 
Hypofractionated Simultaneous integrated boost (SIB) by 
Tomotherapy in a Phase I-II study. 
Materials and Methods: 211 pts ( 78 low- risk[LR], 53 
intermediate- risk [IR] and 80high-risk[HiR]) were treated 
between 2005 and 2011. IR and HiR pts received 51,8 Gy on 
pelvic lymph-nodes (LN) and concomitant SIB to prostate up 
to 74,2Gy in 28 fr; LR pts were treated to the prostate to 
71,4Gy in 28fr. Androgen deprivation (AD) was delivered to 
33%,43% and 88% of LR/IR/HiR pts for a median time of 6, 12 
and 34 months (m) respectively. The gastrointestinal (GI) and 
genitourinary (GU) late toxicities were recorded according to 
the RTOG scoring system. Biochemical relapse free (bRFS) 
survival (Phoenix definition), cancer-specific (CCS) and 
overall survival (OS) actuarial curves were assessed. Selected 
clinical/dosimetry variables were tested as potential 
predictors of GI /GU toxicity and of BCR/CCS/OS (Cox test) . 
Results: Median follow was 60m. The 5-year incidence of late 
toxicity was: GU≥ 2 : 20.2 %; GU ≥G3 : 5.9% ; GI≥2 : 17%; 
GI≥3: 6,3%.The prevalence at the last control was: GU ≥G2: 
7.1%, ≥G3: 1.9% ; GI ≥G2:5.2%, ≥G3: 1.9%. Best predictors of 
≥G3 GU and GI late toxicity were GU acute toxicity≥G2 ( [HR] 
:4.9) and previous surgery (HR:3.4) respectively. The overall 
5-year bRFS was 93.7% (LR: 94.6%; IR: 96.2%; HiR: 91.1%); OS 
was 88.6% ( LR:90.5%; IR: 87.4%; HR: 87%) and CSS was 97.5% 
(LR: 98.7%;IR:95%;HiR: 94.3%). AD and class risk were not 
correlated with bRFS/OS/CSS. 
Conclusions: The combination of pelvic LN irradiation and 
high dose to the prostate (EQD2=88Gy) delivered with daily 
image-guided, intensity-modulated, moderate 
hypofractionation resulted in an excellent 5-year outcome, 
even in IR/HiR patients. The 5-year toxicity profile was 
acceptable with G3 incidences around 6%. The drastically 
reduced prevalence at the last follow-up for both ≥G2 and 
≥G3 toxicities shows that symptoms were recovered in most 
patients. 
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Purpose/Objective: Patient reported outcomes (PRO) are 
important in the assessment of morbidity following treatment 
for prostate cancer, and may detect more late toxicity from 
radiotherapy than clinician reported outcomes. The CHHiP 
trial (Conventional or Hypofractionated High dose intensity 
modulated radiotherapy in Prostate cancer) randomised 
patients with early or intermediate risk localised prostate 
cancer to a standard arm of 74Gy/37f versus experimental 
arms of 60Gy/20f or 57Gy/19f and included a PRO substudy.  
Materials and Methods: PROs of overall bowel bother 
(primary endpoint) and overall urinary bother (key secondary 
endpoint) were assessed as single items within UCLA-PCI and 
EPIC-50 quality of life instruments. These were completed at 
baseline, pre-radiotherapy (pre-RT), 10 weeks, 6, 12, 18 and 
24 months post radiotherapy. All tests were conducted 
between the control group and each experimental arm. A 
significance level of 0.001 was used with 99% confidence 
intervals to allow for multiple testing. A difference in overall 
bowel or urinary bother score at 24 months was tested using 
the chi-squared test for trend. Kaplan-Meier methods were 
used to assess time to 'small' bother, with differences 
between arms assessed using the log-rank test. The odds of 
an increase in bother from pre-RT to 24 months were 
modelled using ordered logistic regression. 
Results: 2011 patients consented to the PRO substudy. 
Return rates were 1659 patients (82.5%) pre-RT and 1444 
(71.8%) at 24 months. 139 PRO pre-RT and 172 PRO at 24 
months dated outside pre-determined acceptable time 
intervals were excluded from fixed timepoint analyses A 
temporary increase in any bother was seen at 10 weeks 
indicative of acute radiation toxicity (from 408/1498 (27.2%) 
pre-RT to 741/1308 (56.7%) at 10 weeks). Cross-sectional 
analysis at 24 months showed no difference between 




No differences were seen in time to small overall bowel 
bother (74Gy vs 60Gy: hazard ratio (HR) 1.11 99% CI: (0.85-
1.46), p=0.32; 74Gy vs 57Gy: HR 0.97 (0.73-1.28), p=0.77) or 
small overall urinary bother (74Gy vs 60Gy: HR 0.99 (0.74-
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1.31), p=0.91; 74Gy vs 57Gy: HR 1.02 (0.74-1.30), p=0.86). 
Analysis of change from pre-RT showed no evidence of a 




The odds of an increase in overall bowel bother were reduced 
(compared to the 74Gy control arm) by 11% (odds ratio (OR) 
0.89 99% CI: (0.62-1.27), p=0.4) and 8% (OR 0.92 (0.77-1.10), 
p=0.24) in the 60Gy and 57Gy groups respectively. For overall 
urinary bother, odds of an increase were increased by 31% 
(OR 1.31, (0.93-1.85) p=0.04) and 2% (OR 1.02 (0.86-1.20), 
p=0.79) for the 60Gy and 57Gy groups respectively. 
Conclusions: Overall bowel bother and overall urinary bother 
was low in the CHHiP trial, cross sectional and longitudinal 
analysis found no evidence of differences between either 
hypofractionated arm and the 74Gy control arm to 24 months 
of follow up.  
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Purpose/Objective: To evaluate the feasibility and 
preliminary toxicity results of a prospective randomized 
multicenter phase II trial of short vs. protracted urethra-
sparing stereotactic body radiotherapy (SBRT) for localized 
prostate cancer. 
Materials and Methods: A total of 93 cT1-3a N0 M0 prostate 
cancer patients with a lymph-node involvement risk ≤ 20% 
were randomized between September 2012 and October 2014 
to be treated with an SBRT protocol of 36.25 Gy in 5 fractions 
of 7.25 Gy either over 9 days (Arm A, n=45) or over 28 days 
once-a-week, the same week-day (Arm B, n=48). The dose to 
the prostatic urethra with a surrounding margin of 3 mm 
(urethral planning risk volume, uPRV) was reduced to 32.5 Gy 
in 5 fractions (NTD2Gy of 74 and 62 Gy for an α/β ratio of 1.5 
and 3 Gy, respectively). Tolerance to the treatment was 
scored using the Common Toxicity Criteria for Adverse Events 
ver. 4.0 grading scale, the International Prostate Symptom 
Score (IPSS) and the EORTC QLQ-PR25 quality of life (QoL) 
questionnaire. Thirty-seven patients in Arm A and 38 patients 
in Arm B have completed treatment. Their follow-up (FU) 
extended up to 18 months and in Arm A 70% has reached their 
six month evaluation, while 60% of the patients in Arm B did. 
Results: SBRT was delivered to all patients as planned with 
no treatment interruptions. Overall genitourinary and 
gastrointestinal toxicities were below the stopping rule 
established for the study, with grade 2 toxicity reported in 6 
patients for each arm mostly after the 5th fraction. Only one 
patient experienced late grade 3 rectal toxicity, with the 
need of blood transfusion and endoscopic coagulation for the 
bleeding, between the 7th and 12th month FU. Mean IPSS 
scores increased significantly between baseline and the 5th 
fraction (p<0.01) in both treatment arms, returning to 
baseline at week 12. Mean IPSS values at baseline, after the 
5th fraction and after 12 weeks were 7.5, 14 and 7.5 for Arm 
A and 8.1, 12.7 and 8.9 for Arm B, respectively. No 
significant differences were observed in EORTC QLQ-PR25 
QoL endpoints between baseline and week 12 in either study 
arm.  
Conclusions: Preliminary results demonstrated the feasibility 
and the acceptable toxicity rates of this short vs. protracted 
urethra-sparing prostate SBRT phase II trial. Three months 
after randomization complete recovery from side effects and 
return to baseline IPSS scores was observed in both treatment 
schedules.  
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Purpose/Objective: The combination of adjuvant hormone 
therapy (HT) with radiotherapy (RT) improves prognosis in 
patients with intermediate-high risk prostate cancer (PCa). 
